Transgene Biotek Ltd.
Snapshot View

3.21 -0.11 ▼-3.3%

27 June 2022, 04:01:00 PM
Volume: 40,379

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.transgenebiotek.com
Market Cap 26.22 Cr.
Enterprise Value(EV) 36.33 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) -1.37 Trailing Twelve Months Ending 2022-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2022-03
Industry PE 39.15 Trailing Twelve Months Ending 2022-03
Book Value / Share 1.56 Trailing Twelve Months Ending 2022-03
Price to Book Value 2.06 Calculated using Price: 3.21
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 7.58 Cr. 75,770,000 Shares
FaceValue 10
Company Profile
Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-3.31%
1 Week
-5.31%
1 Month
-9.32%
3 Month
-17.90%
6 Month
-27.87%
1 Year
-29.61%
2 Year
-52.02%
5 Year
+8.81%
10 Year
-83.62%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) -0.64 -50.54 -9.63 -11.78 -17.03 -11.57 -18.31 -28.73 -38.00
Return on Capital Employed (%) -0.54 -47.36 -8.84 -10.85 -14.68 -6.74 -14.83 -22.10 -26.55
Return on Assets (%) -0.55 -36.70 -5.45 -6.56 -7.77 -3.35 -4.84 -6.39 -6.45

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03* Rs. Cr.
Shh. Funds 322 206 191 174 59 52 44 33 22 17
Non Curr. Liab. 12 127 127 127 127 120 120 120 120 121
Curr. Liab. 35 26 25 11 12 14 13 14 14 9
Minority Int.
Equity & Liab. 369 358 344 313 198 187 177 167 157 147
Non Curr. Assets 348 338 326 310 197 186 176 166 156 146
Curr. Assets 21 20 18 3 1 1 1 1 1 1
Misc. Exp. not W/O
Total Assets 369 358 344 313 198 187 177 167 157 147

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. TTM
Net Sales 15 1 0 0 0 0 0 0 0
Other Income 0 1 0 0 1 7 2 0 0 0
Total Income 15 2 0 0 1 7 2 0 0 0
Total Expenditure -16 -3 -2 -1 -3 -2 -1 -1 -1 -1
PBIDT -1 -1 -2 -1 -2 5 1 -1 0 0
Interest 0 0 0 0 -1 0 0 0 0
Depreciation -1 -17 -17 -21 -18 -10 -10 -10 -10 -10
Taxation -1
Exceptional Items -115
PAT -2 -133 -19 -22 -20 -6 -9 -11 -10 -10
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit -2 -133 -19 -22 -20 -6 -9 -11 -10 -10
Adjusted EPS 0 -18 -3 -3 -3 -1 -1 -1 -1 -1

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 25 13 -2 4 6 0 -1 -2 0 0
Cash Fr. Inv. -144 -15 1 -5 -6 3 2 0
Cash Fr. Finan. 83 2 1 1 -2 0
Net Change -36 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 23.64 23.64 23.64 23.64 23.64 23.64 23.64 23.64 23.64
Public 76.36 76.36 76.36 76.36 76.36 76.36 76.36 76.36 76.36
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 08 Jun 2022
Revised Declaration Of Unmodified Opinion On Standalone And Consolidated Audited Annual Financial Results For Year Ended 31 March 2022.
With reference to email from BSE Ltd dated 7th June 2022 we hereby submit revised Declaration of unmodified opinion on Standalone and Consolidated Audited Annual Financial Results for year ended 31 March 2022 along with complete financial results.
Thu, 02 Jun 2022
REVISED COMPLIANCE CERTIFICATE AS PER CLAUSE 40(9).
We are enclosing hereto the Revised Compliance Certificate As Per Clause 40(9) in the prescribed format for the year ended 31st March 2022
Mon, 30 May 2022
Board Meeting Outcome for Outcome Of Board Meeting
This with reference to our letter dated May 08 2022.

Acordingly the Board has Considered and Approved the Audited Consolidated
& Stand-alone Financial Statement for the Quarter and Financial Year ended
31.03.2022 in accordance with the Indian Accounting Standards (IND-AS) as per
Companies (Indian Accounting Standards) Rules 2015 along with Auditors Report
submitted by M/s. Manisha Dubey & Associates Chartered Accountants.

This is for your kind information and records.

Technical Scans View Details

Mon, 27 Jun 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Decrease 3 Months High Decrease 3 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 200,572.41 835.95 +1.4%
Divi's Laboratories Ltd. 97,518.56 3,679.05 0.0%
Cipla Ltd. 75,086.75 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. 71,855.08 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. 54,559.09 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. 48,438.53 2,858.25 -0.6%
Gland Pharma Ltd. 43,775.42 2,658.60 +0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 61.29 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2022-03 32.99 3,679.05 0.0%
Cipla Ltd. Consolidated 2022-03 29.83 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.92 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 51.70 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 62.24 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2022-03 36.13 2,658.60 +0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 4.18 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2022-03 8.33 3,679.05 0.0%
Cipla Ltd. Consolidated 2022-03 3.60 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.74 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 9.68 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8.12 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2022-03 6.12 2,658.60 +0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 0.10 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,658.60 +0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 14.13 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,658.60 +0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 14.13 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,658.60 +0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,658.60 +0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 835.95 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,679.05 0.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 932.25 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,317.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,795.45 -1.0%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,858.25 -0.6%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,658.60 +0.6%

FAQ's On Transgene Biotek Ltd.

Can I Buy Transgene Biotek Shares now?

What is the Share Price of Transgene Biotek?

What is the Relative Strength Index (RSI) Value of Transgene Biotek?

What is the Market Capital (MCAP) of Transgene Biotek?

What are the key metrics to analyse Transgene Biotek?

What is the Price Performance of Transgene Biotek?